Physician profile
Phyllis Jackson
NPI 1043649627
$5,080.75
in general payments reported to CMS, 2019-2025
44 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,848 · 2022: $1,653 · 2023: $740 · 2024: $365 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.84 | 2021-2025 | |
| Harmony Biosciences LLC | $427.40 | 2021-2023 | Wakix |
| Teva Pharmaceuticals USA, INC. | $384.48 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $362.26 | 2021-2025 | Zilbrysq, Rystiggo, Briviact |
| Biohaven Pharmaceutical Holding Company Ltd. | $343.91 | 2022 | |
| Jazz Pharmaceuticals INC. | $288.16 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $279.24 | 2021 | |
| Lilly USA, LLC | $265.74 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Acorda Therapeutics, INC | $182.28 | 2021-2023 | Inbrija |
| Amgen INC. | $178.94 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $163.05 | 2021-2025 | Crexont, Rytary |
| Acadia Pharmaceuticals INC | $136.60 | 2021-2025 | Nuplazid |
| Eisai INC. | $136.24 | 2022-2025 | |
| Biogen, INC. | $88.02 | 2022-2025 | Vumerity, Spinraza |
| Avanir Pharmaceuticals, INC. | $80.34 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.